Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)
Please see here for more information.Study Objectives & Details: Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.
- Enrollment: This trial is active and currently enrolling.
- How to Participate: For more information, call 617-643-5833 and/or email: firstname.lastname@example.org
- Who Can Participate: Anyone between the ages of 1-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.
- Age Range: 1-55 years
- Gender: Any
- Desired Keywords: Food allergy, peanut allergy, oral immunotherapy
- Estimated Time Commitment (# of visits, ): This is a multi-stage study, with an individual study participation of up to 4 years and 5 months, but not past December 2023.
- Study Location: Massachusetts General Hospital/ ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=&term=CoFAR11&cntry=&state=&city=&dist=
- Compensation: Provided
- Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Site Principal Investigator: Wayne Shreffler, MD, PhD , Study Coordinator: Michael Marget , Study Primary Investigator: Robert Wood, MD